Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

What impact does Trump's megabill have on US economy? Why did Tesla's deliveries drop sharply this quarter? How will expiration of US EV tax credits affect sales? What caused French air traffic strike disruptions? Why are crypto firms seeking bank charters now? How will the US-Vietnam trade deal impact tariffs? What drove S&P 500 to new record highs today?

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

benzinga.com/cannabis/25/07/46194289/atai-life-sciences-and-merger-partner-set-up-psychedelic-depression-therapy-with-encouraging-late-stage-

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with…

This story appeared on benzinga.com, 2025-07-01 13:28:24.